【ChiCTR-ICR-15006619】比效玻璃體注射類固醇(triamcinolone acetonide)及抗血管內皮生長因子藥物(ranibizumab)聯合療法和單一注射抗血管內皮生長因子藥物(ranibizumab)治療新生血管老年性黃斑病變之療效及安全性的前膽性研究
ChiCTR-ICR-15006619
尚未开始
/
/
/
2015-06-17
/
/
triamcinolone acetonide, ranibizumab, neovascular age-related macular degeneration
比效玻璃體注射類固醇(triamcinolone acetonide)及抗血管內皮生長因子藥物(ranibizumab)聯合療法和單一注射抗血管內皮生長因子藥物(ranibizumab)治療新生血管老年性黃斑病變之療效及安全性的前膽性研究
比效玻璃體注射類固醇(triamcinolone acetonide)及抗血管內皮生長因子藥物(ranibizumab)聯合療法和單一注射抗血管內皮生長因子藥物(ranibizumab)治療新生血管老年性黃斑病變之療效及安全性的前膽性研究
比效玻璃體注射類固醇(triamcinolone acetonide)及抗血管內皮生長因子藥物(ranibizumab)聯合療法和單一注射抗血管內皮生長因子藥物(ranibizumab)治療新生血管老年性黃斑病變之療效及安全性的前膽性研究
随机平行对照
治疗新技术
Randomized
Single-blind
Novartis Pharmaceuticals (HK) Ltd.
/
50
/
2015-06-30
1990-01-01
/
1. Patients with active subfoveal CNV of all types (including predominantly classic, minimally classic, occult, and retinal angiomatous proliferation) secondary to AMD; 2. Age beyond 50 years old; 3. Only one eye are suffering from CNV; 4. Best-corrected visual acuity (BCVA) between 20/32 and 20/320 measured on Early Treatment of Diabetic Retinopathy Study (ETDRS) charts; 5. Lesions do not exceed 12 disk areas; 6. No more than 50% of the lesions could be occupied by subretinal hemorrhage; 7. Pseudophakic eyes; 8. Patients can give consent.；
请登录查看1. Eyes with subfoveal fibrosis or atrophy, retinal pigment epithelial tear involving the macula, or subretinal hemorrhage involving the center of the fovea (>50% of the total CNV area); 2. Eyes have been treated for AMD with intraocular anti-VEGF therapy or are previous treatment with verteporfin photodynamic therapy or laser photocoagulation within the past 3 months; 3. Intraocular surgery within the past 2 months or likely to be performed during the study period; 4. Documented diabetic retinopathy, uncontrolled glaucoma, and CNV not related to AMD; 5. History or presence of intraocular inflammation or infection; 6. History of glaucoma and on more than one topical medication; 7. History of glaucoma filtering surgery in the study eye; 8. Family history of glaucoma.；
请登录查看Department of Ophthalmology and Visual Sciences, The Chinese University of Hong Kong
/
Department of Ophthalmology and Visual Sciences, The Chinese University of Hong Kong的其他临床试验
Department of Ophthalmology and Visual Sciences, The Chinese University of Hong Kong的其他临床试验
最新临床资讯
-
Nat Rev Clin Oncol｜AI赋能肿瘤临床试验：从流程优化到证据生成的全景透视
智药邦2026-08-12
-
康臣药业1类新药糖肾方“芪箭颗粒”获NMPA临床研究许可
康臣药业2026-08-12
-
璎黎药业2026-08-12
-
幂方健康基金2026-08-12
-
细胞与基因治疗领域2026-08-12
-
云南白药2026-08-12
-
细胞治疗前沿2026-08-12
-
广州达博生物制品有限公司2026-08-12
-
医药笔记2026-08-12
-
医药笔记2026-08-12
全球药物研发中心
全球研发数据与行业前沿情报
研发动态
相关报告
政策法规
-
2026-08-13
-
2026-08-13
-
2026-08-13
-
摩熵咨询 20 8
-
摩熵咨询 34 27
-
摩熵咨询 20 5
-
颁布机构：四川省经济和信息化厅、中共四川省委军民融合发展委员会办公室、四川省教育厅、四川省科学技术厅、四川省人力资源和社会保障厅、四川省卫生健康委员会、四川省医疗保障局、四川省中医药管理局、四川省药品监督管理局 2026-08-04
-
颁布机构：国家医保局 2026-07-31
-
颁布机构：国家药品审评中心（CDE） 2026-07-24
医药市场洞察中心
医药市场销售数据分析 · 智能洞察 · 竞争格局监测
-
医药市场销售数据分析 · 医院、实体药店、网上药店
-
市场竞争格局分析(靶点、药品类型、ATC大类)
市场动态
市场报告
政策法规
-
2026-08-13
-
2026-08-13
-
2026-08-13
-
摩熵咨询 35 36
-
摩熵咨询 28 38
-
摩熵咨询 34 18
-
颁布机构：国家市场监督管理总局 2026-08-10
-
颁布机构：国家市场监督管理总局 2026-05-29
-
颁布机构：国家市场监督管理总局 2026-05-29